LONDON – U.S.-based Novavax has begun a late stage trial of its potential COVID-19 vaccine in the United Kingdom because the high-level of the coronavirus circulating in the country is likely to produce quick results, the pharmaceutical company said.Novavax plans to test the effectiveness of its vaccine in a trial involving 10,000 people between the ages of 18 and 84, according to a statement issued late Thursday.
At least 25% of the subjects will be over the age of 65, and 400 participants will also receive a licensed flu vaccine.The trial is being conducted in partnership with the U.K.
government’s Vaccine Taskforce, which was created in April to help speed the development of a COVID-19 vaccine. “With a high level of SARS-CoV-2.